TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$350 Million



Lead Manager, January 2024

2.50% Senior Convertible Notes

Immunocore Holdings plc (“Immunocore” or the “Company”) (IMCR) is a commercial stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune diseases. Leveraging their proprietary, flexible, off-the-shelf ImmTAX platform, they are developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and earlier pre-clinical programs across three therapeutic areas.

More Like This

Mar 2024

Exchange of all Outstanding Series B Convertible Preferred Stock for Common Stock

Financial Advisor

View Details >
May 2022
$82 Million

Series C Convertible Preferred

Exclusive Placement Agent

View Details >
Nov 2021
$690 Million

1.50% Senior Convertible Notes


View Details >